Status:
COMPLETED
Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent
Lead Sponsor:
Bracco Diagnostics, Inc
Conditions:
Steno-occlusive Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is an explorative small pilot study comparing two MRA contrast agents, one of which has been on the market for a few years and the other fairly new to the market. Since the study is explorative a...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Known or suspected renovascular disease based on one of the following criteria:
- severe hypertension
- hypertension refractory to standard therapy
- abrupt onset of moderate to severe hypertension at age \< 35 years
- normalized blood pressure by an ACE inhibitor in a patient with moderate or severe hypertension
- unexplained by stable elevation of serum creatinine \> 2Mg/dL
- positive findings for stenosis from another imaging modality
Exclusion
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00415805
Start Date
December 1 2006
End Date
February 1 2009
Last Update
August 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bracco Imaging, S.p.A
Milan, Italy, 20134